Related Experiment Video

Updated: Apr 19, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Cardioprotective effects of ghrelin in heart failure: from gut to heart

Mahalaqua Nazli Khatib1, Padam Simkhada2, Dilip Gode3

  • 1Department of Physiology, JNMC, Wardha, Maharashtra, India.

Heart Views : the Official Journal of the Gulf Heart Association
|December 25, 2014
PubMed

Insights

Ghrelin shows cardioprotective effects in heart failure (HF) models, suggesting therapeutic potential. Further research is needed to understand its mechanisms and evaluate ghrelin as a biomarker for chronic heart failure (CHF).

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) significantly contributes to morbidity and mortality.
  • Ghrelin, particularly its acylated form, exhibits cardioprotective effects in experimental heart failure (HF) models.
  • These findings have led to proposals for ghrelin's use in HF treatment.

Purpose of the Study:

  • To investigate the underlying mechanisms of ghrelin's cardioprotective effects in heart failure.
  • To explore the therapeutic potential of ghrelin for patients with CHF.
  • To evaluate ghrelin as a potential biomarker and prognostic tool in CHF.

Main Methods:

  • Review of existing literature on ghrelin's effects in HF models.
  • Analysis of exploratory human clinical studies.
  • Identification of knowledge gaps regarding ghrelin's mechanism of action in CHF.

Main Results:

  • Cardioprotective effects of ghrelin have been observed in preclinical HF models.
  • Exploratory human studies provide preliminary evidence for ghrelin's potential benefits.
  • The precise mechanisms underlying these protective effects remain largely undetermined.

Conclusions:

  • Ghrelin demonstrates promise for the treatment of chronic heart failure.
  • Further research is essential to elucidate ghrelin's mechanisms of action.
  • Ghrelin warrants investigation as a potential biomarker and therapeutic agent for CHF.

Keywords:
Cardioprotective effectsghrelingut

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.3K
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.9K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
592
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.6K